ImmunityBio, Inc. — Director's Dealing 2021

Oct 9, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ImmunityBio, Inc. (IBRX)
CIK: 0001326110
Period of Report: 2021-10-08

Reporting Person: Adcock Richard (Director, CEO & President)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-10-08	Common Stock	P	7	$9	Acquired	7	Indirect
2021-10-08	Common Stock	P	1923	$8.805	Acquired	1930	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	86176	Direct

Footnotes

F1: Shares held by girlfriend living in the same household as the Reporting Person. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that such reporting person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.